Skip to content
BIO Events
M&A comeback may face political headwinds, say BIO CEO panelists
When it comes to biotech M&A, 2024 wasn’t a great year, but it wasn’t “horrible,” according to analysts at the BIO CEO & Investor Conference ...
Read More
Latest News
LATEST STORIES
Federal Policy
House members urge passage of reforms at PBM hearing
The time has come for Congress to pass legislation to prevent pharmacy benefit managers (PBMs) from inflating drug costs, limiting patient access to drugs, and ...
Health
EPIC Act introduced to correct IRA’s ‘pill penalty’
Bipartisan legislation reintroduced in the House on Feb. 21 would encourage the development of small-molecule drugs by eliminating the “pill penalty” in the Inflation Reduction ...
Health
Kidney Action Week: 4 things you need to know about kidney disease
“Kidney disease is a major and growing public health concern,” LaVarne A. Burton, American Kidney Fund President and CEO, said in an interview with Bio.News. ...
WHAT YOU MISSED AT THE LATEST BIO EVENTS
M&A comeback may face political headwinds, say BIO CEO panelists
When it comes to biotech M&A, 2024 wasn’t a great year, but it wasn’t “horrible,” according to analysts at the BIO CEO & Investor Conference ...
Read More
BIO coffee chat focuses on reimbursement for Accelerated Approval Pathway drugs
The U.S. Food and Drug Administration’s Accelerated Approval Pathway enables the timely development of treatments for severely ill patients who have few if any other ...
Read More